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| INTRODUC TI ON
Gastric cancer is the fourth most common cancer and is the second leading cause of cancer-related death worldwide.
1 As a result of a lack of characteristic early symptoms, most GC are already advanced when diagnosed. Despite numerous studies, no reliable diagnostic or prognostic indicators have yet been discovered, and the prognosis of advanced GC is poor. Therefore, investigation into the molecular mechanisms of GC pathogenesis is urgently needed in order to find effective biomarkers for early diagnosis and new treatments.
Leucine-rich repeat neuronal protein-1 is a type I transmembrane protein with extracellular leucine-rich repeats. LRRN1 belongs to the mammalian leucine-rich neuronal protein family (LRRN1-LRRN5), [2] [3] [4] [5] LRRN proteins are mainly expressed in nerve tissues, but they are also expressed to a lesser degree in the lungs, heart, liver, and kidneys. LRRN proteins have a high degree of homology.
Studies have shown that LRRN proteins play an important role in the processes of nerve development and regeneration. In addition to their expression in normal tissues, LRRN family members are also expressed in tumors. LRRN2 is amplified and overexpressed in glioblastoma and anaplastic astrocytoma, and LRRN3 has been isolated and cloned from the overexpressed proto-oncogene c-Ha-ras in rat fibrosarcoma cells. 6 However, the role of the LRRN family in cancer, especially in GC, is not fully understood.
LRRN1, one of the members of the LRRN family, has been identified as a prognostic factor for high-risk neuroblastoma (NB) and was found to promote tumor cell proliferation. 7 LRRN1 is a direct transcriptional target of MYCN and it potentiates EGFR and IGFR signaling, which further promotes MYCN transcription. 8 Moreover, LRRN1 also plays an important role in maintaining the stability of pluripotency-related proteins through AKT phosphorylation, thus helping to maintain the pluripotency and self-renewing capacities of human embryonic stem cells. 9 MYCN, EGFR, IGFR, and AKT also participate in GC development, invasion, and metastasis. However, it is unknown whether LRRN1 plays a similar role in other tumors.
In the present study, we found that LRRN1 is upregulated in GC tissue samples and its expression is closely related to poor prognosis. Knocking down LRRN1 expression promoted GC cell apoptosis, accompanied by activation of the Fas/FasL pathway. These results
show that LRRN1 suppresses GC cell apoptosis through inhibition of the Fas/FasL pathway.
| MATERIAL S AND ME THODS

| Bioinformatics analysis
Expression data of normal tissue and GC tissue datasets were downloaded from TCGA (https://cancergenome.nih.gov).
GES62254 was downloaded from the Gene Expression Omnibus database (GEO) (https ://www.ncbi.nlm.nih.gov/geo) to verify the results obtained from the TCGA datasets. Kaplan-Meier Plotter (https ://www.kmplot.com/analysis) was used to draw Kaplan-Meier survival curves of patients with different expression levels of LRRN1. When survival analysis was carried out, the "Exclude GSE62254" option was checked because GSE62254 has markedly different characteristics than the other datasets. GSEA was carried out using GSEA Java software by comparing the expression of genes in the LRRN1-high/low groups divided by the median expression level of LRRN1. KEGG signaling pathways were used as a reference in this step to evaluate the pathways that LRRN1 may modulate.
| Cell cultures
Human GC cell line HGC-27 (TCHu 22) 
| siRNA transfection
Transfection was carried out according to the siRNA sequences transfection protocol for Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). Sequence of the LRRN1-specific siRNA was 5′-UUGUGGACACUCACUAUUCTT-3′, Fas-specific siRNA was 5′-CAAGGAUGUUUAAAAUCUATT-3′, and JUN-specific siRNA was 5′-GGCACAGCUUAAACAGAAA-3. Nonsense RNAi (5′-UUCUCCGAACGUGUCACGUTT-3′) was used as NC. Transfection efficiency was identified at 48 hours after transfection.
| rRNA-depleted RNA-Seq
Total RNA was extracted using the mirVana miRNA Isolation Kit (Ambion, Foster City, CA, USA) following the manufacturer's protocol. RNA integrity was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Samples with RNA integrity number ≥7 were subjected to the subsequent analysis. The libraries were constructed using TruSeq Stranded Total RNA with Ribo-Zero Gold (San Diego, CA, USA)
according to the manufacturer's instructions. These libraries were then sequenced on the Illumina sequencing platform (HiSeqTM 2500 or other platform) and 150 bp/125 bp paired-end reads were generated.
| Generation of stable LRRN1 knocked-down cell line
Negative control or LRRN1-shRNA lentiviral particles were obtained 
| Colony formation assay
In order to detect the long-term effects of the expression of LRRN1 on cell viability, 500 cells/well were added to 12-well culture plates for 2 weeks. The cells were fixed with methanol and then stained with 0.5% crystal violet, and the colonies were counted using Image-Pro Plus. 
| Reverse transcription-polymerase chain reaction
Total RNA was extracted with TRIZOL (Invitrogen) reagent. For mRNA detection, reverse transcription was carried out using the PrimeScript RT Reagent Kit with gDNA Eraser (Takara Bio, Kusatsu, Japan). cDNA generated from 1000 ng total RNA using SYBR 
| Western blot analysis
Cells were solubilized in 1% Triton lysis buffer (1% Triton X-100, 50 mM Tris-Cl pH 7.4, 150 mM NaCl, 10 mM EDTA, 100 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, 2 μg/mL aprotinin). 
| Enzyme-linked immunosorbent assay
Protein level of FasL in cell culture supernatants was measured by FasL ELISA kit (R&D Systems) according to the manufacturer's instructions. 
| TUNEL
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| Immunohistochemistry analysis
Immunohistochemical staining was carried out using a streptavidinperoxidase procedure. LRRN1, protein expression was investigated using antibodies as mentioned above. All other reagents were from
Sigma. Specificity of all antibodies was confirmed by western blotting.
For statistical analysis, immunostaining was considered positive when the tumor mass occupied more than 10% of the cross-sectional core area and when 10% or more of the neoplastic cells were stained.
| Statistical analysis
Experimental results were reported as mean ± standard deviation and Student's t tests were used for comparisons between two groups.
Multivariate analysis was carried out using the multivariate Cox proportional hazards model, which was fitted using all of the clinicopathological variables. Chi-squared test was used to evaluate the correlation between LRRN1 expression levels and the clinical characteristics. All means were calculated from at least three independent experiments. P < 0.05 was considered statistically significant.
| RE SULTS
| Leucine-rich repeat neuronal protein-1 is significantly upregulated in GC and is related to poor prognosis
To clarify the role of LRRN1 in GC, we compared 32 pairs of GC and corresponding non-cancerous gastric samples from the same individuals using TCGA database (https ://cance rgeno me.nih. gov). We found that LRRN1 was significantly upregulated in the F I G U R E 3 Leucine-rich repeat neuronal protein-1 (LRRN1) knockdown inhibits proliferation and enhances apoptosis in gastric cancer (GC) cells. A,B, HGC-27 and SNU-216 cells were infected with negative control (NC) or LRRN1-shRNA lentiviral particles. LRRN1 expression levels were detected by qRT-PCR (A) and western blotting (B) analyses. C, Cell viability assays show that LRRN1 knockdown decreased GC cell proliferation. D, Number of colonies formed by GC cells transfected with LRRN1-shRNA was fewer than those transfected with NC. E, Western blot shows that knocking down LRRN1 suppressed AKT and ERK pathways. F, Flow cytometry shows that apoptosis in the siLRRN1 group exceeded that in the NC group. Error bar = SEM, *P < 0.05, **P < 0.01 indicates statistically significant difference
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GC samples ( Figure 1A ). To further confirm this, we measured LRRN1 mRNA and protein expression in seven GC cell lines and the normal gastric epithelial cell line GES1. LRRN1 was found to be upregulated significantly in the GC cell lines ( Figure 1B,C) .
We then used Kaplan-Meier analysis to examine the association between LRRN1 expression and patient prognosis. As shown in Figure 1D ,E, high expression of LRRN1 was associated with shorter overall survival. Similar results were obtained when disease-free survival (DFS) was analyzed ( Figure 1F ). For further analysis, the patients were divided into two groups: the LRRN1- (Table 2 ). These results show that LRRN1 is upregulated in GC and that high LRRN1 expression is associated with poor prognosis.
| Leucine-rich repeat neuronal protein-1 suppresses GC cell apoptosis
To further investigate the role of LRRN1 in GC, GSEA was carried out. We found that DNA replication, apoptosis, and cell cycle pathways were significantly enriched when LRRN1 expression was low ( Figure 3A ,B). LRRN1 knockdown significantly decreased the proliferation of HGC-27 and SNU-216 cells ( Figure 3C ). Moreover, the LRRN1-shRNA-transfected group formed fewer colonies than the NC-shRNA-transfected group ( Figure 3D ). Knocking down LRRN1 also significantly inhibited the ERK and AKT pathways ( Figure 3E ).
Flow cytometry indicated that knocking down LRRN1 significantly increased the apoptosis of HGC-27 and SNU-216 cells (HGC-27 siNC vs siRNA, P = 0.024; SNU-216 siNC vs siRNA, P = 0.018) ( Figure 3F ).
To further validate these results, we next overexpressed LRRN1 in the SGC-7901 and AGS cell lines which express a low level of LRRN1
( Figure 4A,B) , and the results were opposite of those seen in the LRRN1 knockdown cells (Figure 4C,D) . These results show that LRRN1 expression impacts apoptosis in GC cells.
| Leucine-rich repeat neuronal protein-1 inhibits GC cell apoptosis by suppressing the Fas/ FasL pathway
To further clarify the mechanism by which LRRN1 regulates the apoptosis of GC cells, we measured the expression levels of apoptotic pathway proteins that may be regulated downstream. As shown in Figure 5A , more evident activation of the extrinsic apoptotic pathway than the intrinsic pathway was observed. The Fas/FasL pathway, one of the most important components of the extrinsic apoptotic pathway, was significantly upregulated after LRRN1 knockdown ( Figure 5A,B) . We also found that either antibody-mediated depletion of FasL or knockdown of Fas ( Figure 5C ) could eliminate the proapoptotic effect of LRRN1 knockdown ( Figure 5D-F) . In conclusion, our results suggest that LRRN1 regulates the apoptosis of GC cells through the Fas/FasL pathway. 
| Leucine-rich repeat neuronal protein-1 suppresses GC cell apoptosis in vivo
To investigate whether LRRN1 can suppress the apoptosis of GC cells in vivo, HGC-27-shNC and HGC-27-shLRRN1 cells were injected into nude mice s.c. near the scapula. Xenograft tumors in which LRRN1
was knocked down grew more slowly than those that received the control shRNA ( Figure 7A-C) . Using a TUNEL assay, we showed that LRRN1 knockdown promoted GC cell apoptosis in vivo ( Figure 7D ), which was consistent with our in vitro results. c-jun, Fas, and FasL were upregulated in the HGC-27-shLRRN1 xenograft tumors compared to the HGC-27-shNC tumors, which was also consistent with the in vitro results ( Figure 7E ). the present study show that LRRN1 expression is an independent prognostic factor of GC associated with poor prognosis. Also, high expression level of LRRN1 suppresses GC cell apoptosis by inhibiting the Fas/FasL pathway.
| D ISCUSS I ON
Previously, LRRN1 was identified as a prognostic factor for highrisk NB. 7, 8 It was also reported that LRRN1 expression was higher in MYCN-amplified primary neuroblastomas than in nonamplified ones, and that MYCN could upregulate LRRN1. 7 It was also reported that LRRN1 positively regulates cell proliferation through activation of the extracellular signal-regulated kinase mediated by EGF and IGF-1. 8 However, the significance and the role of LRRN1 in GC remain uncertain. In the present study, we showed that LRRN1 is widely upregulated in GC and that this correlates with poor prognosis and worsened clinicopathology. We then determined the prognostic value of LRRN1 in GC. Patients with higher LRRN1 expression had a poorer prognosis, whereas those with lower expression had a longer survival. Univariate and multivariate Cox regression analyses indicated that LRRN1 expression was an independent prognostic factor for GC. Based on these results, LRRN1 may be a potential biomarker for GC.
In order to elucidate the role of LRRN1 in the occurrence and development of GC, we knocked down LRRN1 in HGC-27 GC cells.
Bioinformatics analysis was used to determine which pathways LRRN1 may modulate, and apoptosis is one of these pathways.
Apoptosis is an essential process for the homeostasis of multicellular organisms. Strict regulation of apoptosis plays a vital role in cancer.
12
There are two main pathways of apoptotic cell death: one involves interactions of cell surface receptors, such as Fas and tumor necrosis factor-α1, with their ligands, whereas the second pathway involves the mitochondria. 13 We used flow cytometry to detect apoptosis in GC cell lines with knocked down LRRN1, and the results showed that knocking down LRRN1 enhanced the apoptosis of GC cells.
We then examined changes to the apoptotic signaling pathways after knocking down LRRN1. The results suggest that the extrinsic apoptotic pathway, rather than the intrinsic pathway, is affected by LRRN1. The extrinsic apoptotic pathway is triggered by cell death ligands, leading to Fas-associated death domain protein-dependent caspase-8 activation and mitochondrial-independent cell death. activity. There are some limitations to the present study, and further comprehensive and in-depth clinical analyses are needed to ensure that LRRN1 can be used as a biomarker. The mechanism by which LRRN1 regulates AP-1 has not been elucidated fully and still needs further study. In this study, we confirmed that LRRN1 plays a significant role in GC. Importantly, LRRN1, an independent prognostic factor for GC, attenuates the apoptosis of GC cells and may serve as a potential prognostic biomarker and therapeutic target. 
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